Malignant Endometrial Polyps in Postmenopausal Breast Cancer Tamoxifen-Treated Patients
Identifieur interne : 000759 ( Main/Merge ); précédent : 000758; suivant : 000760Malignant Endometrial Polyps in Postmenopausal Breast Cancer Tamoxifen-Treated Patients
Auteurs : Ilan Cohen [Israël] ; Joel Bernheim [Israël] ; Ron Azaria [Israël] ; Ron Tepper [Israël] ; Reuven Sharony [Israël] ; Yoram Beyth [Israël]Source :
- Gynecologic Oncology [ 0090-8258 ] ; 1999.
English descriptors
- KwdEn :
- Teeft :
- Benign, Benign endometrial polyps, Beyth, Breast cancer, Breast cancer patients, Carcinoma, Common endometrial pathology, Complex hyperplasia, Cordoba, Diagnostic hysteroscopy, Endometrial, Endometrial cancer, Endometrial pathology, Endometrial polyps, Endometrial thickness, Endometrium, Gynecol, Gynecol oncol, Healthy postmenopausal controls, Healthy women, Hyperplasia, Hysteroscopy, Malignant, Malignant changes, Malignant endometrial polyps, Malignant polyps, Ndings, Obstet gynecol, Operative hysteroscopy, Polyp, Postmenopausal, Postmenopausal breast cancer patients, Postmenopausal patients, Postmenopausal women, Risk factors, Small focus, Such patients, Tamoxifen, Tamoxifen treatment, Transvaginal.
Abstract
Abstract: Background. Endometrial polyps are the most common endometrial pathology described in association with postmenopausal tamoxifen exposure. It is generally accepted that the occurrence of malignancy in endometrial polyps among healthy women is up to 0.5%. However, no one has yet described the incidence of this malignant transformation among postmenopausal breast cancer tamoxifen-treated patients. Objective. The aim of this study was to study the exact rate of malignant changes in endometrial polyps recovered from postmenopausal breast cancer tamoxifen-treated patients. Methods. We reviewed the pathological results and medical records of all postmenopausal breast cancer patients in whom endometrial polyps were recovered following at least 6 months of tamoxifen treatment in our institute. We also looked for the rate of malignant changes in polyps recovered from all healthy postmenopausal controls with endometrial polyps in our institute during the period of the study. Results. Two (3.0%) of 67 endometrial polyps recovered from postmenopausal breast cancer tamoxifen-treated patients revealed malignant features. None of the clinical variables tested, including risk factors for endometrial cancer, was significantly different between the groups. In the controls only 5 (0.48%) of 1034 polyps were malignant. Conclusion. Up to 3.0% of endometrial polyps recovered from postmenopausal breast cancer tamoxifen-treated patients may show malignant changes. This rate is higher than that found in our controls as well as that reported in the general female population.
Url:
DOI: 10.1006/gyno.1999.5558
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000478
- to stream Istex, to step Curation: 000477
- to stream Istex, to step Checkpoint: 000463
Links to Exploration step
ISTEX:FF286F786E10E8C53EEA4011FE67E22B5643D33FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant Endometrial Polyps in Postmenopausal Breast Cancer Tamoxifen-Treated Patients</title><author><name sortKey="Cohen, Ilan" sort="Cohen, Ilan" uniqKey="Cohen I" first="Ilan" last="Cohen">Ilan Cohen</name></author><author><name sortKey="Bernheim, Joel" sort="Bernheim, Joel" uniqKey="Bernheim J" first="Joel" last="Bernheim">Joel Bernheim</name></author><author><name sortKey="Azaria, Ron" sort="Azaria, Ron" uniqKey="Azaria R" first="Ron" last="Azaria">Ron Azaria</name></author><author><name sortKey="Tepper, Ron" sort="Tepper, Ron" uniqKey="Tepper R" first="Ron" last="Tepper">Ron Tepper</name></author><author><name sortKey="Sharony, Reuven" sort="Sharony, Reuven" uniqKey="Sharony R" first="Reuven" last="Sharony">Reuven Sharony</name></author><author><name sortKey="Beyth, Yoram" sort="Beyth, Yoram" uniqKey="Beyth Y" first="Yoram" last="Beyth">Yoram Beyth</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FF286F786E10E8C53EEA4011FE67E22B5643D33F</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1006/gyno.1999.5558</idno><idno type="url">https://api.istex.fr/document/FF286F786E10E8C53EEA4011FE67E22B5643D33F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000478</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000478</idno><idno type="wicri:Area/Istex/Curation">000477</idno><idno type="wicri:Area/Istex/Checkpoint">000463</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000463</idno><idno type="wicri:doubleKey">0090-8258:1999:Cohen I:malignant:endometrial:polyps</idno><idno type="wicri:Area/Main/Merge">000759</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Malignant Endometrial Polyps in Postmenopausal Breast Cancer Tamoxifen-Treated Patients</title><author><name sortKey="Cohen, Ilan" sort="Cohen, Ilan" uniqKey="Cohen I" first="Ilan" last="Cohen">Ilan Cohen</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar-Saba, 44281, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Bernheim, Joel" sort="Bernheim, Joel" uniqKey="Bernheim J" first="Joel" last="Bernheim">Joel Bernheim</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Pathology, Sapir Medical Center, Kfar-Saba, 44281, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Azaria, Ron" sort="Azaria, Ron" uniqKey="Azaria R" first="Ron" last="Azaria">Ron Azaria</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar-Saba, 44281, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Tepper, Ron" sort="Tepper, Ron" uniqKey="Tepper R" first="Ron" last="Tepper">Ron Tepper</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar-Saba, 44281, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Sharony, Reuven" sort="Sharony, Reuven" uniqKey="Sharony R" first="Reuven" last="Sharony">Reuven Sharony</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar-Saba, 44281, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Beyth, Yoram" sort="Beyth, Yoram" uniqKey="Beyth Y" first="Yoram" last="Beyth">Yoram Beyth</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar-Saba, 44281, Affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Gynecologic Oncology</title><title level="j" type="abbrev">YGYNO</title><idno type="ISSN">0090-8258</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1999">1999</date><biblScope unit="volume">75</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="136">136</biblScope><biblScope unit="page" to="141">141</biblScope></imprint><idno type="ISSN">0090-8258</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0090-8258</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>endometrial polyps</term><term>malignant changes</term><term>tamoxifen</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Benign</term><term>Benign endometrial polyps</term><term>Beyth</term><term>Breast cancer</term><term>Breast cancer patients</term><term>Carcinoma</term><term>Common endometrial pathology</term><term>Complex hyperplasia</term><term>Cordoba</term><term>Diagnostic hysteroscopy</term><term>Endometrial</term><term>Endometrial cancer</term><term>Endometrial pathology</term><term>Endometrial polyps</term><term>Endometrial thickness</term><term>Endometrium</term><term>Gynecol</term><term>Gynecol oncol</term><term>Healthy postmenopausal controls</term><term>Healthy women</term><term>Hyperplasia</term><term>Hysteroscopy</term><term>Malignant</term><term>Malignant changes</term><term>Malignant endometrial polyps</term><term>Malignant polyps</term><term>Ndings</term><term>Obstet gynecol</term><term>Operative hysteroscopy</term><term>Polyp</term><term>Postmenopausal</term><term>Postmenopausal breast cancer patients</term><term>Postmenopausal patients</term><term>Postmenopausal women</term><term>Risk factors</term><term>Small focus</term><term>Such patients</term><term>Tamoxifen</term><term>Tamoxifen treatment</term><term>Transvaginal</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Background. Endometrial polyps are the most common endometrial pathology described in association with postmenopausal tamoxifen exposure. It is generally accepted that the occurrence of malignancy in endometrial polyps among healthy women is up to 0.5%. However, no one has yet described the incidence of this malignant transformation among postmenopausal breast cancer tamoxifen-treated patients. Objective. The aim of this study was to study the exact rate of malignant changes in endometrial polyps recovered from postmenopausal breast cancer tamoxifen-treated patients. Methods. We reviewed the pathological results and medical records of all postmenopausal breast cancer patients in whom endometrial polyps were recovered following at least 6 months of tamoxifen treatment in our institute. We also looked for the rate of malignant changes in polyps recovered from all healthy postmenopausal controls with endometrial polyps in our institute during the period of the study. Results. Two (3.0%) of 67 endometrial polyps recovered from postmenopausal breast cancer tamoxifen-treated patients revealed malignant features. None of the clinical variables tested, including risk factors for endometrial cancer, was significantly different between the groups. In the controls only 5 (0.48%) of 1034 polyps were malignant. Conclusion. Up to 3.0% of endometrial polyps recovered from postmenopausal breast cancer tamoxifen-treated patients may show malignant changes. This rate is higher than that found in our controls as well as that reported in the general female population.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000759 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000759 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:FF286F786E10E8C53EEA4011FE67E22B5643D33F
|texte= Malignant Endometrial Polyps in Postmenopausal Breast Cancer Tamoxifen-Treated Patients
}}
| This area was generated with Dilib version V0.6.33. |  |